Panoramic Capital LLC Takes Position in Halozyme Therapeutics, Inc. $HALO

Panoramic Capital LLC acquired a new position in Halozyme Therapeutics, Inc. (NASDAQ:HALO) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 116,416 shares of the biopharmaceutical company’s stock, valued at approximately $9,112,000. Halozyme Therapeutics comprises 3.9% of Panoramic Capital LLC’s portfolio, making the stock its 8th biggest holding. Panoramic Capital LLC owned 0.10% of Halozyme Therapeutics at the end of the most recent reporting period.

Other hedge funds have also recently made changes to their positions in the company. Arrowstreet Capital Limited Partnership raised its position in Halozyme Therapeutics by 29.5% in the third quarter. Arrowstreet Capital Limited Partnership now owns 3,290,665 shares of the biopharmaceutical company’s stock valued at $241,337,000 after purchasing an additional 749,484 shares during the period. Bank of America Corp DE purchased a new position in shares of Halozyme Therapeutics during the second quarter worth $214,504,000. William Blair Investment Management LLC purchased a new position in shares of Halozyme Therapeutics during the second quarter worth $196,540,000. Dimensional Fund Advisors LP grew its stake in shares of Halozyme Therapeutics by 1.2% in the fourth quarter. Dimensional Fund Advisors LP now owns 2,104,157 shares of the biopharmaceutical company’s stock valued at $141,613,000 after buying an additional 25,731 shares in the last quarter. Finally, Norges Bank acquired a new stake in shares of Halozyme Therapeutics in the fourth quarter valued at $128,201,000. Hedge funds and other institutional investors own 97.79% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on HALO. Morgan Stanley decreased their target price on Halozyme Therapeutics from $96.00 to $93.00 and set an “overweight” rating on the stock in a research note on Tuesday, May 12th. Wells Fargo & Company lifted their target price on Halozyme Therapeutics from $75.00 to $95.00 and gave the company an “equal weight” rating in a research report on Friday, August 7th. Citizens Jmp increased their price target on shares of Halozyme Therapeutics from $92.00 to $93.00 and gave the stock a “market outperform” rating in a research report on Friday, August 7th. Leerink Partners raised shares of Halozyme Therapeutics from a “market perform” rating to an “outperform” rating and raised their price objective for the company from $83.00 to $110.00 in a research note on Friday, August 7th. Finally, Benchmark restated a “buy” rating on shares of Halozyme Therapeutics in a report on Tuesday, July 21st. Nine analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $91.20.

Insider Transactions at Halozyme Therapeutics

In related news, Director Mahesh Krishnan sold 7,304 shares of Halozyme Therapeutics stock in a transaction that occurred on Monday, June 29th. The shares were sold at an average price of $75.00, for a total value of $547,800.00. Following the completion of the transaction, the director owned 14,462 shares in the company, valued at $1,084,650. The trade was a 33.56% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Helen Torley sold 20,000 shares of the business’s stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $104.18, for a total transaction of $2,083,600.00. Following the transaction, the chief executive officer owned 767,780 shares of the company’s stock, valued at $79,987,320.40. This trade represents a 2.54% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 64,103 shares of company stock valued at $5,226,496. 2.50% of the stock is currently owned by corporate insiders.

Halozyme Therapeutics Trading Down 2.1%

NASDAQ:HALO opened at $107.06 on Thursday. The firm has a market cap of $12.15 billion, a PE ratio of 31.96, a price-to-earnings-growth ratio of 0.44 and a beta of 0.85. The stock has a fifty day moving average price of $85.50 and a 200 day moving average price of $74.39. Halozyme Therapeutics, Inc. has a 12-month low of $61.22 and a 12-month high of $109.66. The company has a current ratio of 2.71, a quick ratio of 2.31 and a debt-to-equity ratio of 13.50.

Halozyme Therapeutics (NASDAQ:HALO) last issued its quarterly earnings results on Thursday, August 6th. The biopharmaceutical company reported $2.28 earnings per share for the quarter, topping the consensus estimate of $1.79 by $0.49. The company had revenue of $481.00 million for the quarter, compared to the consensus estimate of $402.28 million. Halozyme Therapeutics had a return on equity of 260.98% and a net margin of 24.86%.Halozyme Therapeutics’s revenue was up 47.7% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.54 EPS. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. Sell-side analysts anticipate that Halozyme Therapeutics, Inc. will post 7.77 earnings per share for the current fiscal year.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.